A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Details

Language :

English

ISSN :

00064971 and 15280020

Volume :

140

Issue :

1, Number 1 Supplement 1

Database :

Supplemental Index

Journal :

Blood

Publication Type :

Periodical

Accession number :

ejs62897932

Full Text :

https://doi.org/10.1182/blood-2022-167008